Cwm, LLC Chinook Therapeutics, Inc. Transaction History

Cwm, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	BUY	$18.66 - $38.58 $37,506 - $77,545	2,010 Added 170.34%	3,190 $123,000
Q3 2020 Sep 15, 2021	BUY	$11.4 - $15.5 $13,452 - $18,290	1,180 New	1,180 $17,000
Q3 2020 Oct 19, 2020	SELL	$11.4 - $15.5 $13,452 - $18,290	-1,180 Closed	0 $0
Q2 2020 Sep 15, 2021	BUY	$10.7 - $16.85 $12,626 - $19,883	1,180 New	1,180 $17,000
Q2 2020 Jul 22, 2020	SELL	$10.7 - $16.85 $12,626 - $19,883	-1,180 Closed	0 $0
Q1 2020 Sep 15, 2021	BUY	$5.75 - $19.35 $6,785 - $22,833	1,180 New	1,180 $17,000
Q1 2020 Apr 28, 2020	SELL	$5.75 - $19.35 $6,785 - $22,833	-1,180 Closed	0 $0
Q4 2019 Sep 14, 2021	BUY	$4.68 - $6.1 $5,522 - $7,198	1,180 New	1,180 $17,000
Q4 2019 Jan 27, 2020	SELL	$4.68 - $6.1 $5,522 - $7,198	-1,180 Closed	0 $0
Q3 2019 Sep 14, 2021	BUY	$5.25 - $7.85 $6,195 - $9,263	1,180 New	1,180 $17,000
Q3 2019 Oct 22, 2019	SELL	$5.25 - $7.85 $6,195 - $9,263	-1,180 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$7.7 - $22.05 $9,086 - $26,019	1,180 New	1,180 $17,000
Q2 2019 Jul 31, 2019	SELL	$7.7 - $22.05 $9,086 - $26,019	-1,180 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$12.1 - $21.5 $14,278 - $25,370	1,180 New	1,180 $0

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

Stay updated on Cwm, LLC with notifications on news.